Nuveen LLC Invests $10.80 Million in AngioDynamics, Inc. $ANGO

Key Points

• Nuveen LLC acquired over 1.15 million shares of AngioDynamics, Inc., worth approximately $10.8 million, representing 2.83% of the company's total shares as per their recent SEC filing.
• The company reported earnings of ($0.03) per share, exceeding analysts' expectations and reflecting a 13% increase in revenue year-over-year, totaling $80.16 million.
• Several analysts have upgraded their ratings on AngioDynamics, with target prices ranging from $16.00 to $24.00, indicating a consensus buy rating among research analysts.

Nuveen LLC purchased a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,150,518 shares of the medical instruments supplier's stock, valued at approximately $10,803,000. Nuveen LLC owned about 2.83% of AngioDynamics as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new position in AngioDynamics in the 4th quarter valued at about $387,000. Ameriprise Financial Inc. raised its stake in AngioDynamics by 24.0% in the 4th quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier's stock valued at $2,542,000 after purchasing an additional 53,675 shares during the last quarter. GAMMA Investing LLC raised its stake in AngioDynamics by 1,281.4% in the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock valued at $130,000 after purchasing an additional 12,891 shares during the last quarter. GSA Capital Partners LLP acquired a new position in AngioDynamics in the 1st quarter valued at about $642,000. Finally, New York State Common Retirement Fund raised its stake in AngioDynamics by 667.0% in the 1st quarter. New York State Common Retirement Fund now owns 54,635 shares of the medical instruments supplier's stock valued at $513,000 after purchasing an additional 47,512 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Stock Up 1.2%

Shares of ANGO stock traded up $0.12 during trading hours on Thursday, hitting $10.13. 242,000 shares of the company were exchanged, compared to its average volume of 365,363. The firm has a market cap of $411.58 million, a PE ratio of -12.20 and a beta of 0.67. AngioDynamics, Inc. has a 1 year low of $5.83 and a 1 year high of $13.50. The firm has a fifty day moving average of $9.22 and a 200 day moving average of $9.57.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.09. The business had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The company's revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.06) EPS. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. Analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th. Lake Street Capital assumed coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They issued a "buy" rating and a $24.00 target price for the company. Wall Street Zen raised shares of AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Finally, Canaccord Genuity Group boosted their target price on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $19.00.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.